Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study to Observe the Safety and Efficacy of Etanercept (Enbrel®) in Patients With Moderately Active Rheumatoid Arthritis in Every Day Clinical Practice in Austria

Completed

Conditions: Rheumatoid Arthritis

Interventions: Other: non-intervention

First Posted Date: 2013-06-13

Last Posted Date: 2018-12-03

Lead Sponsor: Pfizer

Target Recruit Count: 111

Registration Number: NCT01877239

Locations: 🇦🇹
Ordination Dr. Maya Thun, Wien, Austria
🇦🇹
Ordination Dr. Peter Peichl, Wien, Austria
🇦🇹
Rheumazentrum Oberlaa, Vienna, Austria

and more 7 locations

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

Phase 1

Terminated

Conditions: Breast Cancer Metastatic

Interventions: Drug: PF-03084014
Drug: Docetaxel

First Posted Date: 2013-06-12

Last Posted Date: 2019-03-15

Lead Sponsor: Pfizer

Target Recruit Count: 30

Registration Number: NCT01876251

Locations: 🇮🇹
Instituto Europeo di Oncologia, Milano, Italy
🇺🇸
Karmanos Cancer Institute (KCI), Detroit, Michigan, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

and more 12 locations

Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: PF-06410293
Biological: Humira (adalimumab-EU)
Biological: Humira (adalimumab-US)

First Posted Date: 2013-06-06

Last Posted Date: 2014-02-14

Lead Sponsor: Pfizer

Target Recruit Count: 210

Registration Number: NCT01870986

Locations: 🇧🇪
Pfizer Investigational Site, Brussels, Belgium

A Study to Investigate the Effect of PH-797804 on QTc Interval

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PH-797804
Drug: Placebo
Drug: Moxifloxacin

First Posted Date: 2013-05-27

Last Posted Date: 2013-08-15

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT01862887

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Long Term Study of Genotropin (Somatropin) for Short Children Born Small for Gestational Age (SGA)

Phase 4

Completed

Conditions: Short Stature Born Small for Gestational Age (SGA)

Interventions: Drug: Genotropin (somatropin)

First Posted Date: 2013-05-22

Last Posted Date: 2016-05-03

Lead Sponsor: Pfizer

Target Recruit Count: 62

Registration Number: NCT01859949

Locations: 🇯🇵
Kitasato University Hospital, Sagamihara, Kanagawa, Japan
🇯🇵
Tohoku University Hospital, Sendai, Miyagi, Japan
🇯🇵
Hiroshima City Hospital, Hiroshima, Japan

and more 16 locations

A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Dacomitinib

First Posted Date: 2013-05-21

Last Posted Date: 2017-07-18

Lead Sponsor: Pfizer

Target Recruit Count: 41

Registration Number: NCT01858389

Locations: 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸
Investigational Drug Service, Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

and more 11 locations

Assial - Anti Tnf Treatment in Ankylosing Spondylitis: an Observational Cohort Study in Italy

Completed

Conditions: Ankylosing Spondylitis

Interventions: Other: no intervention

First Posted Date: 2013-05-17

Last Posted Date: 2017-03-09

Lead Sponsor: Pfizer

Target Recruit Count: 152

Registration Number: NCT01856569

Locations: 🇮🇹
Unita Operativa Semplice di Reumatologia, Catania, CT, Italy
🇮🇹
U.O.S. Reumatologia - Azienda Ospedaliera Universitaria Policlinico Sant'Orsola-Malpighi, Bologna, Italy
🇮🇹
Piazzale Spedali Civili, Brescia, Italy

and more 14 locations

PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: PF-06291874

First Posted Date: 2013-05-17

Last Posted Date: 2018-11-01

Lead Sponsor: Pfizer

Target Recruit Count: 117

Registration Number: NCT01856595

Locations: 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸
Profil Institute for Clinical Research, Inc., Chula Vista, California, United States
🇺🇸
MRA Clinical Research, LLC, South Miami, Florida, United States

Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-05089771

First Posted Date: 2013-05-16

Last Posted Date: 2013-06-25

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT01854996

Locations: 🇧🇪
Pfizer Investigational Site, Brussels, Belgium

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

Phase 3

Terminated

Conditions: Low-grade Serous Ovarian Cancer
Low-grade Serous Fallopian Tube Cancer
Low-grade Serous Peritoneal Cancer

Interventions: Drug: MEK162, MEK inhibitor; oral
Drug: Physician's choice chemotherapy

First Posted Date: 2013-05-09

Last Posted Date: 2023-10-30

Lead Sponsor: Pfizer

Target Recruit Count: 341

Registration Number: NCT01849874

Locations: 🇺🇸
Karmanos Cancer Institute, Farmington Hills, Michigan, United States
🇺🇸
Doris Stein Research Center Building, Los Angeles, California, United States
🇺🇸
James Cancer Hospital & Solove Research Institute, Columbus, Ohio, United States

and more 218 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy